• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma.

作者信息

Pinato David J

机构信息

Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.

出版信息

Oncogene. 2018 Aug;37(34):4635-4638. doi: 10.1038/s41388-018-0262-8. Epub 2018 May 14.

DOI:10.1038/s41388-018-0262-8
PMID:29755128
Abstract
摘要

相似文献

1
Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma.循环游离肿瘤DNA与肝细胞癌疾病表型分析的前景
Oncogene. 2018 Aug;37(34):4635-4638. doi: 10.1038/s41388-018-0262-8. Epub 2018 May 14.
2
Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.液体活检在肝细胞癌中作为预后和预测生物标志物的临床应用：循环肿瘤细胞和循环肿瘤 DNA。
J Exp Clin Cancer Res. 2018 Sep 3;37(1):213. doi: 10.1186/s13046-018-0893-1.
3
Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.肝细胞癌长期随访患者循环肿瘤 DNA 和蛋白质生物标志物的综合液体分析。
Clin Cancer Res. 2019 Sep 1;25(17):5284-5294. doi: 10.1158/1078-0432.CCR-18-3477. Epub 2019 Jun 19.
4
Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.循环肿瘤DNA分析揭示晚期肝细胞癌的克隆进化和实时疾病进展。
Int J Cancer. 2017 Sep 1;141(5):977-985. doi: 10.1002/ijc.30798. Epub 2017 Jun 7.
5
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.循环游离肿瘤 DNA 突变作为肝细胞癌生物标志物的鉴定。
Eur J Cancer. 2019 Jul;116:56-66. doi: 10.1016/j.ejca.2019.04.014. Epub 2019 Jun 4.
6
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.循环肿瘤 DNA 甲基化标志物用于肝细胞癌的诊断和预后。
Nat Mater. 2017 Nov;16(11):1155-1161. doi: 10.1038/nmat4997. Epub 2017 Oct 9.
7
Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.液体活检在肝细胞癌患者中的应用：循环肿瘤细胞和游离核酸。
World J Gastroenterol. 2017 Aug 21;23(31):5650-5668. doi: 10.3748/wjg.v23.i31.5650.
8
Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.采用血浆游离 DNA 进行遗传分析在初治肝细胞癌患者中的应用：一项初步研究。
Ann Oncol. 2018 May 1;29(5):1286-1291. doi: 10.1093/annonc/mdy083.
9
Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.首选末端坐标和体细胞变异作为与肝细胞癌相关的循环肿瘤 DNA 的特征。
Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10925-E10933. doi: 10.1073/pnas.1814616115. Epub 2018 Oct 29.
10
Decreased serum exosomal miR-320a expression is an unfavorable prognostic factor in patients with hepatocellular carcinoma.血清外泌体 miR-320a 表达降低是肝细胞癌患者的预后不良因素。
J Int Med Res. 2020 Apr;48(4):300060519896144. doi: 10.1177/0300060519896144.

引用本文的文献

1
Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with Liquid Biopsy.免疫疗法联合局部区域治疗实现肝癌根治性肝切除术：概念验证显示液体活检可检测到持久生存获益
Cancers (Basel). 2023 Oct 30;15(21):5220. doi: 10.3390/cancers15215220.
2
Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study.利用循环肿瘤 DNA 进行连续监测以预测肝癌患者的早期复发：一项前瞻性研究。
Mol Oncol. 2022 Jan;16(2):549-561. doi: 10.1002/1878-0261.13105. Epub 2021 Oct 4.

本文引用的文献

1
A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.一项对血浆 DNA 进行超深度靶向测序的初步研究鉴定了肝细胞癌中的驱动突变。
Oncogene. 2018 Jul;37(27):3740-3752. doi: 10.1038/s41388-018-0206-3. Epub 2018 Apr 9.
2
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.微小残留病作为急性髓系白血病预后预测和治疗优化的生物标志物。
Expert Rev Hematol. 2018 Apr;11(4):307-313. doi: 10.1080/17474086.2018.1447378. Epub 2018 Mar 7.
3
Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
肝细胞癌下一代测序分析组织和循环肿瘤 DNA：对靶向治疗的影响。
Mol Cancer Ther. 2018 May;17(5):1114-1122. doi: 10.1158/1535-7163.MCT-17-0604. Epub 2018 Feb 26.
4
Genomic Analysis Revealed New Oncogenic Signatures in -Mutant Hepatocellular Carcinoma.基因组分析揭示了KRAS突变型肝细胞癌中的新致癌特征。
Front Genet. 2018 Feb 2;9:2. doi: 10.3389/fgene.2018.00002. eCollection 2018.
5
Breaking Kuhn's paradigm in advanced hepatocellular carcinoma.打破晚期肝细胞癌的库恩范式。
Hepatology. 2018 May;67(5):1663-1665. doi: 10.1002/hep.29714. Epub 2018 Mar 26.
6
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.肠道圆桌会议论文：肝细胞癌近期的部分进展
Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17.
7
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.高突变循环肿瘤 DNA：与基于检查点抑制剂免疫治疗反应的相关性。
Clin Cancer Res. 2017 Oct 1;23(19):5729-5736. doi: 10.1158/1078-0432.CCR-17-1439.
8
Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease.游离DNA血浆浓度与非酒精性脂肪性肝病严重程度的相关性。
J Transl Med. 2017 May 19;15(1):106. doi: 10.1186/s12967-017-1208-6.
9
The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma.肝细胞癌肿瘤内异质性的空间组织和转移的进化轨迹。
Nat Commun. 2017 Feb 27;8:4565. doi: 10.1038/ncomms14565.
10
The clinical role of circulating free tumor DNA in gastrointestinal malignancy.循环游离肿瘤 DNA 在胃肠道恶性肿瘤中的临床作用。
Transl Res. 2017 May;183:137-154. doi: 10.1016/j.trsl.2016.12.006. Epub 2016 Dec 22.